key: cord-0803172-fzzo608d
authors: Kubelac, Paul; Preda, Alexandra; Ciuleanu, Tudor; Todor, Nicolae; Balacescu, Ovidiu; Achimas-Cadariu, Patriciu; Iancu, Dana; Mocan, Cristina; Bandi-Vasilica, Mariana; Lupse, Mihaela; Briciu, Violeta Tincuta; Man, Milena Adina; Vlad, Catalin
title: Outcomes of patients with cancer infected with SARS-CoV-2: results from the Ion Chiricuță Oncology Institute series
date: 2022-02-10
journal: ESMO Open
DOI: 10.1016/j.esmoop.2022.100423
sha: c63ab64ef30ad5d6db03382fc41bfbf9004b75c5
doc_id: 803172
cord_uid: fzzo608d

BACKGROUND: The evolution of COVID-19 is a controversial topic in cancer patients. They have been designated by international organizations as a vulnerable population at greater risk for contracting SARS-CoV2 and having a more severe clinical outcome. PATIENTS AND METHODS: Active screening at our Institution became routine early in the pandemic. We have examined the clinical data of 341 cancer patients, with a positive RT-PCR SARS-CoV2 test between April 2020 and February 2021, in the prevaccination era. RESULTS: During the infection, 40.5% remained asymptomatic, 27.6% developed a mild form, 20.5% had a moderate form, and 11.4% a severe-critical form of COVID-19 that led to death in 7.6% of cases. Treatment was adapted to disease severity according to National guidelines. In our series, the incidence of COVID-19 infection was lower in cancer patients compared to the general population (p<0.001), however, the mortality rate was higher in cancer patients in comparison to the general population (7.6% vs. 2.9%, p<0.001). The prognostic factors were assessed by three distinct univariate and multivariate analyses: a) evolution to a moderate or severe-critical clinical manifestation, b) clinical worsening (severe-critical form or death) and c) overall survival. In the multivariate analysis, the prognostic factors associated with the evolution to a moderate or severe-critical clinical manifestation were: PS (performance status) (p<0.0001) and no active treatment in the previous 3 months (p=0.031). Factors associated with clinical worsening were: PS (p<0.0001), peripheral arterial disease (p=0.03), and chronic liver disease (p=0.04). Factors associated with impaired overall survival were PS (p<0.0001), ischemic cardiac disease (p=0.0126), chronic liver disease (p=0.001), and radiotherapy (p=0.0027). CONCLUSION: Our series confirms a more severe evolution for COVID-19 infection in cancer patients, with PS as the most prominent prognostic factor in all three multivariate analyses. By active screening, efforts should be in place to keep cancer units as Coronavirus-free sanctuaries

The COVID-19 pandemic posed significant problems for the Romanian health system, with 730,056 positive cases and 18,402 deaths recorded until 1 February 2021 and an acceleration trend of the second wave in October-November 2020 with a peak of 10,269 new cases recorded on 18 November 2020 (1).

The Oncology Institute "Prof. Dr. Ion Chiricuta" in Cluj-Napoca, with 550 hospital beds and 25 reusable places in the day hospital, is the oldest in the country and the second-largest in Romania.

Here we present the effects of COVID-19 infection on a series of cancer patients who tested positive at our Institute until 1 February 2021.

Nasopharyngeal samples from patients examined in our Institution between 1 April 2020 and 1 February 2021 (during the first two waves of the pandemic and before any vaccine was available for cancer patients in Romania) were collected.

The first 21 patients were diagnosed until 13 April 2020, at the initial active screening among asymptomatic hospitalized patients. From that point on, all patients were tested at admission, and those found positive were isolated and hospitalized in dedicated COVID-19 treatment units. Those patients who had a diagnosis of malignant tumor treated in our Institution and had full clinical details of SARS-CoV-2 infection outcome were included in the present study.

Samples were collected with cotton swabs in a 3 mL viral transport medium (ViroSan Transport Medium, SaniMed, Romania) and stored at 4⁰ C before RNA extraction. The RNA extraction procedure was performed with PureLink Viral RNA/DNA Mini Kit (#12280050, Thermo Fisher Scientific, Waltham, MA, USA), and Quick-RNA Viral Kit (#R1035, Zymo Research, Irvine, CA, USA) kits.

RT-qPCR assessment of SARS-CoV-2 was performed with EliGene COVID19 BASIC A RT Kit (#90077-RT-A, Elisabeth Pharmacon, Czech Republic), Coronavirus (COVID- 19) Genesig Real-Time PCR assay (#Z-Path-COVID-19-CE, Primer Design, UK). PCR data interpretation was done according to the manufacturer's protocol. The RT-qPCR instruments used in this study were LightCycler480 and Cobas Z480 (Roche, Basel, Switzerland).

The severity of the disease was defined as asymptomatic, mild (without pneumonia), medium (with non-severe pneumonia), and severe/ critical (severe: tachypnea with >30 breaths per minute or oxygen saturation <93% at rest or PaO2/FIO2 <300 mmHg; critical: respiratory failure requiring mechanical ventilation, shock or other organ failure that requires intensive care), according to the first WHO classification (2).

Until August 2020, all patients diagnosed with SARS-CoV2 infection were hospitalized in dedicated units, even if asymptomatic. Starting with September 2020 and the second wave of the pandemic, only symptomatic patients with moderate or severe/ critical forms were hospitalized. The others were observed in isolation at home under the supervision of the family physician. The treatment, in accordance with the national protocol in use, stated that asymptomatic patients required no treatment or vitamin C, D, and Zinc. Mild forms received antiviral treatment with lopinavir/ritonavir, antipyretics. Moderate forms received lopinavir/ritonavir + hydroxychloroquine +/-azithromycin, antipyretics. Severe/ critical forms received antiviral treatment with remdesivir or favipiravir (if available) or lopinavir/ritonavir + hydroxychloroquine + azithromycin + corticosteroid therapy (dexamethasone), tocilizumab, +/-convalescent plasma (and IgG anti-SARS-CoV-2). The treatment of respiratory failure has been adapted to severity, with supplemental oxygen by nasal cannula or oxygen mask, continuous positive airway pressure, or mechanical ventilation. Appropriate anticoagulant therapy (prophylactic or curative) has been prescribed for obese patients at intermediate, high, or very high thromboembolic risk, with thromboembolic clinical manifestations or disseminated intravascular coagulation, as recommended. Analgesic, antipyretic or anti-inflammatory treatments (paracetamol, metamizole, or non-steroidal anti-inflammatory drugs -NSAIDs) and vitamin C, D, and Zinc supplementation have also been added where appropriate at the physician's choice.

Until August 2020, patients were discharged if apyretic, with the improvement of all other symptoms and two consecutive negative nasopharyngeal PCR SARS-CoV-2 tests, at >24 hours interval, after at least 3 days of apyrexia and >7 days from the first positive test. Starting with September 2020, patients were discharged after 10-14 days if considered clinically healed and could leave isolation after 14 days if asymptomatic. Reinfection was defined as a second positive test result more than 180 days from the initial diagnosis.

The main purpose of this analysis was to characterize at diagnosis the prognostic factors for a) evolution to moderate and severe/ critical forms, b) clinical worsening (defined as severe/ critical forms or death), and c) overall survival. Initially, a univariate analysis was performed to identify prognostic factors using the Chi-square test and log-rank test. In the multivariate analysis, the logistic model and the Cox model were used (3) . The threshold for a significant p-value was 0.05. All patient data were anonymized, our study being in accordance with the Declaration of Helsinki.

In the period between 1 April 2020 and 1 February 2021, from a total of 21893 nasopharyngeal swab samples performed, 10143 unique cancer patients were analyzed in our laboratory with a SARS-CoV2 RT-PCR test, with 542 positive individual patients (test positivity rate 5.34%). This figure was significantly lower than the country-level positivity rate for the same period (730,056 positive cases out of 5,601,310 tests, 13.03%, p<0.001) (1). The complete data related to COVID-19 infection could be retrieved for 341 positive cancer patients, and their demographics are presented in Table 1 . A subset of 2 patients had a documented reinfection with SARS-CoV2 at 7 months after the first episode with a subsequent negative RT-PCR test. At diagnosis, among the 341 patients, 164 (48.1%) were asymptomatic, and from the 177 (51.9%) symptomatic forms, 133 (39%) were mild, 37 (10.9%) moderate and 7 (2.1%) severe/ critical. The most common complaints were fatigue (n=152 patients, 44.6%), dry cough (n=98, 28.7%), fever (n=71, 20.8%), dyspnea (n=59, 17.3%), anosmia (n=37, 10.9%) and diarrhea (n=18, 5.3%).

During the course of the infection, 138 (40.5%) patients remained asymptomatic, while 94 (27.6%) developed a mild form, 70 (20.5%) developed a moderate form, and 39 (11.4%) developed a severe/ critical form of COVID-19, Table 2 . The 341 patients, received the following main treatments: paracetamol (n=183, 53.7%), vitamins (n=178, 52.2%), anticoagulants (n=102, 29.9%), antibiotics (other than azithromycin, n=95, 27.9%), corticosteroids (n=71, 20.8%), hydroxychloroquine (n=70, 20.5%), azithromycin (n=60, 17.6%), lopinavir/ritonavir (n=49, 14.4%), NSAIDs (n=30, 8.8%), metamizole (n=16, 4.7%), remdesivir (n=9, 2.6%), favipiravir (n=6, 1.8%), tocilizumab (n=6, 1.8%), darunavir/ritonavir (n=5, 1,5%). No treatment was given to 62 asymptomatic patients (18.2%).

At the time of data analysis, out of the total number of COVID-19 patients, 315 (92.4%) had returned home cured of COVID-19, and 26 patients (7.6%) who developed a severe/ critical form died due to the infection. The median duration until the second negative test was 13 days [limits 7-54].

The median survival of the deceased patients was 17.5 days (range 2-60) after the RT-PCR diagnosis. Four additional patients had a cancer related-death in the 30 days after being considered healed of COVID-19.

Until 1 February 2021, coinciding with database lock, a number of 30,815 COVID-19 related deaths were recorded among a total of 1,073,713 closed cases in Romania (mortality rate 2.9%), which was significantly lower compared with the 7.6% mortality rate in our cancer patients series (p<0.001) (1). The overall survival curve of patients and specific cancer types after COVID-19 infection is presented in Figure 1 . Subgroup analysis of overall survival is presented in Figure  2 .

A first univariate analysis was conducted for the seriousness of the infection (asymptomatic or symptomatic mild vs. symptomatic moderate or severe/ critical form of COVID-19) presented in Table 3 . Factors associated with a worse prognosis in univariate analysis were male gender, advanced active disease or palliation, older age (>65), active or former smoker, PS 2-4, a high number of comorbidities (≥3), selected individual comorbidities (diabetes mellitus, ischemic cardiac disease), hematological malignancies, lung cancer and no active cancer treatment in the previous 3 months. Specifically Other analyzed factors were not significant in univariate analysis and included body mass index, presence of some comorbidities (cerebrovascular disease, peripheral arterial disease, other cardiopathy, deep vein thrombosis and/or pulmonary embolism, chronic obstructive pulmonary disease, chronic kidney disease, chronic liver disease, infections, endocrinopathies or other comorbidities), solid cancers as digestive, breast, gynecological, genitourinary, skin including melanoma, individual cancer treatment methods in the previous 3 months (surgery, radiotherapy, chemotherapy, hormonal therapy, targeted molecular therapy and immunotherapy).

A first multivariate analysis was performed for the eleven factors found significant from the previous univariate analysis. The factors with an independent prognostic value in the multivariate analysis were ECOG PS (HR 3.82, 95% CI 2.11-6.91 for ECOG PS 2-4, p<0.0001) and if a previous cancer treatment was given in the 3 previous months (HR 0.48, 95% CI 0.25-0.94 for treatment given, p=0.031). A third multivariate analysis was performed and included the ten factors from the univariate analysis. The multivariate analysis retained four independent prognostic factors: ECOG PS (HR 82.56, 95% CI 11.26-605.24 for PS 2-4, p<0.0001), ischemic cardiac disease (HR 3.05, 95% CI 1.28-7.3 for the presence of disease, p<0.0126), chronic liver disease (HR 6.85, 95% CI 2. 19-21.38 for the presence of disease, p<0.001) as comorbidities associated with a negative prognosis together with radiotherapy treatment in the last 3 months (HR 4.34, 95% CI 1.67-11.28 for having radiotherapy, p=0.0027), Table 3 . J o u r n a l P r e -p r o o f

The Oncology Institute "Prof. Dr. Ion Chiricuta" from Cluj-Napoca has been significantly affected by the COVID-19 pandemic, however, sustained measures have been taken to counteract the disruption of activity through bimonthly PCR screening of all staff, PCR screening of patients with symptoms suggestive for COVID-19 infection, PCR screening of asymptomatic patients prior to inpatient care, surgical or interventional radiology procedures, radiotherapy sessions or systemic therapy (chemotherapy, immunotherapy, targeted therapy), creation of COVID-19 free pathways and treatment spaces, regular staff and patient information on the correct use of protective equipment. Analysis of our series of patients infected with COVID-19 showed that the incidence among cancer patients was lower than the national incidence. This finding could be explained by the more active prophylactic measures taken by cancer patients (self-isolation, social distancing, mask-wearing, washing hands) who by all means try to avoid COVID-19 infection due to the risks of a more severe evolution and the interference with the anticancer treatments. The higher positivity rate of the national incidence could also be explained by the strict selection criteria for cases tested at the national level, according to the National Institute for Public Health methodology. At a national level, most tests were performed on suspect symptomatic cases, according to the case definition, while in our Institute most cases tested were asymptomatic, and were scheduled for inpatient care or oncological treatments. Active screening with nasopharyngeal PCR was used to screen for SARS-CoV-2 in the asymptomatic phase in almost half of the cases (48%). At the time of diagnosis, 51.9% had one or more symptoms: fatigue, dry cough, fever, dyspnea, anosmia/ ageusia, or diarrhea.

Confirming the results reported by Chinese and Italian authors (4) (5) (6) (7) (8) and not in line with the initial results from the Gustave Roussy Institute (9), in our series the mortality rate for the closed cases of COVID-19 in patients with cancer was significantly higher compared to the general population in Romania (7.6% vs. 2.9%, p<0.01, RR=2.7). These local results can constitute a quantitative argument for Romanian doctors to recommend vaccination as an efficient weapon to transform COVID-19 into a preventable disease for their cancer patient population. None of the patients included in the present analysis were vaccinated, given that the vaccination program for oncological patients started on 1 February 2021 in Romania.

In univariate analysis, in our series, the factors with a pejorative prognosis related both to a moderate or severe/ critical evolution of COVID-19 infection, clinical worsening (severe/ critical form and/or death), and an impaired survival with COVID-19 infection were male gender, advanced active cancer, a declined PS (2-4), and presence of diabetes as an individual comorbidity.

We identified additional factors that were predictive for a moderate or severe/ critical evolution of COVID-19 infection such as age over 65, active or former smoker, more than 3 comorbidities, ischemic cardiac disease, hematological malignancies, lung cancer, and no specific cancer treatment in the previous three months.

Factors that were predictive for clinical worsening of COVID-19 infection included peripheral arterial disease, chronic liver disease, hematological malignancies, and no specific surgical cancer treatment in the previous three months, with breast cancer having a better outcome.

Factors that were negatively correlated with survival due to COVID-19, included age over 65, ischemic cardiac disease, chronic obstructive pulmonary disease, chronic liver disease, digestive tumors, and radiotherapy in the last 3 months.

Zhang et al. studied the outcomes of cancer patients with COVID-19 and found more than fourfold higher likelihood of experiencing severe events in those who received therapy in the preceding 14 days of COVID-19 diagnosis (11) .

To assist healthcare facilities, leading oncology societies such as the European Society of Medical Oncology, the American Society of Clinical Oncology, National Comprehensive Cancer Network have developed guidelines to mitigate the negative effects of the COVID-19 pandemic on the diagnosis and treatment of cancer patients (15) (16) (17) .

The drugs used in >50% of patients were paracetamol and vitamins and in 20%-30% anticoagulants, antibiotics, hydroxychloroquine. Among the approved drugs for SARS-CoV-2, corticoids, authorized in the severe forms following the RECOVERY study (18, 19) , were used in 20.8% of patients in our series. Other authorized medications, the antiviral agent remdesivir and also the monoclonal anti-IL6 antibody tocilizumab (20) (21) (22) (23) , considered active in the severe/ critical forms, and convalescent plasma transfusion were administered in <5% of the patients. No anti-SARS-CoV-2 therapeutic antibodies and no vaccines were available in the studied period. The number of patients treated with each drug and the retrospective nature of the study does not support any conclusions about their effectiveness.

Although the COVID-19 pandemic has posed obstacles to the conduct of the activity at the Oncology Institute "Prof. Dr. Ion Chiricuta", the introduction of protective measures and systematic screening of the virus for the staff and patients (before inpatient treatment and major diagnostic and therapeutic procedures), were implemented in an effort to keep the Institute virusfree with a dedicated buffer department.

In our series the mortality of COVID-19 infection appeared to be greater among cancer patients compared with the general population.

Performance status was the only independent prognostic factor found in all our multiple multivariate analysis, related both to an evolution towards a moderate or severe/ critical form, to clinical worsening and to an impaired survival with COVID-19. 

On multivariate analysis, PS 2-4 was the only independent predictor for a moderate or severe/ critical evolution, clinical worsening, and overall survival (p<0.0001) due to SARS-CoV2 in our series. Additionally, the multivariate analysis highlighted other independent prognostic factors for a moderate or severe/ critical evolution of COVID-19 (absence of cancer treatment in the previous 3 months, statistical trend for the hematological malignancies), for clinical worsening (peripheral arterial disease, chronic liver disease) and for overall survival (ischemic cardiac disease

Prognostic factors for clinical worsening in a univariate analysis were PS >1, hematological malignancies, cancer treatment in the last 3 months and chemotherapy in the last 3 months. Only PS remained significant for clinical worsening in a multivariate analysis. In the same series, prognostic factors for COVID-19 survival in a univariate analysis were PS, disease status (active/ metastatic) and chemotherapy treatment in the last 3 months

Patients presenting with pneumonia (OR 2.7), consolidation (OR 2), bilateral involvement of the lungs (OR 2.8), and pleural effusion (OR 2.7) had a higher risk of death. In multivariate analysis, the factors significantly related to a fatal evolution of COVID-19 infection were PS ≥2 (OR 3.7), stage IV (OR 1.9), active smoker or ex-smoker status (OR 2), corticosteroids use before the diagnosis of COVID-19 (OR 1.8), age over 65 years (OR 1.5). Chemotherapy and targeted molecular therapy were not correlated to a higher risk of death and immunotherapy had a lower risk of mortality (OR 0.6) (14). Based on these results, the authors developed a nomogram that predicts mortality in patients with chest tumors and COVID-19. Patients receive a score based on ECOG PS, stage, smoking/ non-smoking status, age, steroid use, and the type of systemic treatment. For example, a 70-year-old smoker with an ECOG 2 PS who received third-line chemotherapy with docetaxel for a stage IV squamous carcinoma has a score of 260 that translates into a risk of death of over 60%. A 50-year-old non-smoker with an ECOG 0 who receives first-line therapy

Fundamentals of Biostatistics: Cengage Learning

Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Clinical Characteristics of Coronavirus Disease 2019 in China

Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Abstract CT403: Outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments

Patients with Cancer Appear More Vulnerable to SARS-CoV-2: A Multicenter Study during the COVID-19 Outbreak

Clinical characteristics of COVID-19-infected cancer patients: a retrospective case study in three hospitals within Wuhan

Case-Fatality Rate and Characteristics of Patients Dying in Relation to COVID-19 in Italy

Risk of COVID-19 for patients with cancer

COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registrybased, cohort study

Coronavirus disease 2019 (COVID-19) resources for the cancer care community

COVID-19 and cancer

Dexamethasone in Hospitalized Patients with Covid-19

Covid-19: Low dose steroid cuts death in ventilated patients by one third, trial finds

Remdesivir for the Treatment of Covid-19 -Final Report

Remdesivir for 5 or 10 Days in Patients with Severe Covid-19

Tocilizumab in patients with severe COVID-19: a retrospective cohort study

Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial

MBV reports support for attending meetings and/or travel from ROCHE, PFIZER, ACCORD, SERVIER, outside the submitted work. CV reports grants from Romanian National Authority for Scientific Research, COST Association, outside the submitted work. All other authors have nothing to declare.